Third Quarter Highlights: - Record revenues of $77.8 million, up 11% from the prior year - Earnings per share of $0.19, a 36% increase over last year and a 27% increase over the second quarter of 2007 - Operating cash flow of
nearly $14 million - Launch of eight new food and beverage products
containing life'sDHA(TM)
COLUMBIA, Md., Sept. 5 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) today announced its financial results for the third quarter of fiscal 2007, which ended July 31, 2007. Revenues for the third quarter were $77.8 million, up 11% from $70.4 million in the third quarter of fiscal 2006. Net income was $6.1 million, or $0.19 per diluted share, compared with $4.6 million, or $0.14 per diluted share, in last year's third quarter.
Commenting on the quarter, Chief Executive Officer Steve Dubin said, "Martek's improved financial performance this quarter resulted from growth in both sales of DHA for uses other than infant formula and sales of DHA and ARA to infant formula customers, combined with an improved gross margin. We have dedicated much time and effort on the Company's key 2007 focus areas: increasing penetration in international infant formula markets; expanding the use of DHA outside of infant formula; improving gross margin and profitability and developing new products to support future growth. These efforts are beginning to pay off as indicated by this quarter's operating results."
Third Quarter and Year-to-Date Revenue Summary
Product sales in the third quarter increased 12% to $74.5 million and
contract manufacturing sales totaled $3.4 million compared to $4.0 million
in contract manufacturing sales a year ago. The decl
'/>"/>
| SOURCE Martek Biosciences Corporation Copyright©2007 PR Newswire. All rights reserved |